New analysis of Gazyva® shows the drug significantly reduces disease activity in adults with systemic lupus erythematosus.

Phase 3 trial data show that obinutuzumab significantly reduces disease activity in very active extrarenal lupus.

Cutaneous lupus erythematosus is a chronic autoimmune disease with few treatment options and no approved targeted therapies.

More than three-quarters of lupus patients taking obinutuzumab (Gazvya) had a significant improvement in their symptoms after a year on the drug, researchers reported March 6 in The New England ...

Johnson & Johnson's nipocalimab has been granted U.S. Food and Drug Administration Fast Track designation as a potential ...

People with lupus often need to use medicines to manage their symptoms. Although there are many oral medicines that treat lupus, some people with more severe symptoms may not get enough benefit from ...

For the millions of people living with lupus – a chronic autoimmune disease that can damage the kidneys, brain and other ...

Lupus is more common in Black people, and symptoms can be different too. Here's what to look out for and how to treat it.

Lupus is a chronic autoimmune disease in which your immune system mistakenly attacks healthy tissues throughout your body. Weight changes are common with lupus. Some people gain weight, while others ...

Lupus can make you more vulnerable to infection, including UTIs. This susceptibility is associated with changes in your immune system’s response. Lupus, an autoimmune condition, weakens your immune ...